Wales Medical Equipments, Pharmaceuticals and Personal Care Products Tenders & Contracts

Smart Triage First Responder Kits for Welsh Ambulance Services University NHS Trust

This contract covers the supply of Covaris consumables required to support laboratory and diagnostic activities.The consumables are proprietary to Covaris equipment and are specifically designed to be fully compatible with existing systems in use. Due to this proprietary nature, Covaris is the original equipment manufacturer (OEM) and the only supplier able to provide suitable consumables. There are no equivalent third-party alternatives available that meet the required technical specifications without posing risks to equipment performance, reliability, or warranty.As a result, this procurement has been undertaken on a single supplier basis to ensure continuity of service, maintain system integrity, and support ongoing laboratory operations.

This contract covers the supply of Covaris consumables required to support laboratory and diagnostic activities. The consumables are proprietary to Covaris equipment and are specifically designed to be fully compatible with existing systems in use. Due to this proprietary nature, Covaris is the original equipment manufacturer (OEM) and the only supplier able to provide suitable consumables. There are no equivalent third-party alternatives available that meet the required technical specifications without posing risks to equipment performance, reliability, or warranty. As a result, this procurement has been undertaken on a single supplier basis to ensure continuity of service, maintain system integrity, and support ongoing laboratory operations.

Public Health Wales is required to maintain continuity of the existing serology service provision where equipment and infrastructure is in place.The current Serology Managed Service Contract is with Abbott Laboratories Ltd, which began 23rd November 2015. The MSC also incorporates third-party suppliers who provide and maintain key laboratory infrastructure and consumables. Their contributions are critical to delivering a seamless and comprehensive serology testing service across both operational sites.The contract was originally awarded following a competitive open tender process on a 7-year basis and was extended for three additional years in 2022, allowing for a new contract end date of 22nd November 2025. Due to significant risks to patient care, diagnostic turnaround times, and public health surveillance, any disruption to serology testing services would severely impact the ability detect and control infectious diseases such as measles, mumps, rubella, HIV, and hepatitis. Given the critical nature of these services, ensuring continuity through a reliable, compatible managed service arrangement is essential for safeguarding public health and maintaining service integrity.The proposed Direct Award is limited to the continuation of the existing provision to mitigate risk for a 9 months + 3 months period.

The Cardiff and Vale Health Board submitted a bid for funding to replace aged Heart and Lung Machines critical for patient care and continuity of service. The award includes the capital purchase of Heart and Lung Machines with Cooler Heater Units plus associated 10 year maintenance on all equipment provided

Public Health Wales is required to maintain continuity of the existing serology service provision where equipment and infrastructure is in place. The current Serology Managed Service Contract is with Abbott Laboratories Ltd, which began 23rd November 2015. The MSC also incorporates third-party suppliers who provide and maintain key laboratory infrastructure and consumables. Their contributions are critical to delivering a seamless and comprehensive serology testing service across both operational sites. The contract was originally awarded following a competitive open tender process on a 7-year basis and was extended for three additional years in 2022, allowing for a new contract end date of 22nd November 2025. Due to significant risks to patient care, diagnostic turnaround times, and public health surveillance, any disruption to serology testing services would severely impact the ability detect and control infectious diseases such as measles, mumps, rubella, HIV, and hepatitis. Given the critical nature of these services, ensuring continuity through a reliable, compatible managed service arrangement is essential for safeguarding public health and maintaining service integrity. The proposed Direct Award is limited to the continuation of the existing provision to mitigate risk for a 9 months + 3 months period.

Provision of Fungitell Kinetic Assay for Public Health Wales for the detection of (1-3)-Beta-D-glucan (BDG) in body fluids, particularly blood, for the diagnostic indication of fungal infection in line with the NICE sepsis pathway testing regime. Fungitell is the only kit system specified within the NICE guidelines as part of the sepsis pathway that is clinically validated.

This agreement is for standard and custom procedure packs.

The All Wales Medical Genomics Service (AWMGS) has routinely utilised Multiplex Ligation-Dependent Probe Amplification (MLPA) as a diagnostic tool for identifying Copy Number Variations (CNVs)—including deletions and duplications—across a range of genetic disorders. This testing supports clinical decision-making and patient treatment strategies.MLPA technology involves the use of oligonucleotide probe pairs that hybridise to specific DNA sequences within target genes. When both probes bind adjacently at a site of interest, they are ligated and subsequently amplified via Polymerase Chain Reaction (PCR). The amplified DNA fragments are then separated by capillary electrophoresis and analysed to detect CNVs.Since its inception, AWMGS has exclusively sourced MLPA probes and reagents from MRC Holland, a Netherlands-based supplier recognised for its specialised products in molecular diagnostics.

Advanced laboratory and clinical device used worldwide to assess neuromuscular performance and joint function.

Advanced laboratory and clinical device used worldwide to assess neuromuscular performance and joint function.

Hywel Dda University Health Board (HDUHB) has identified a requirement to purchase an Oral Performance Instrument for use within the Speech and Language Therapy Department. The Iowa Oral Performance Instrument is a clinical tool used to measure and improve the strength of the tongue and lips. Procurement of this device will support the assessment and treatment of patients with Dysphagia (swallowing disorders), assist with speech therapy interventions, and aid rehabilitation following illness or injury. The device will enable clinicians to objectively measure oral muscle strength and deliver targeted therapy programmes, supporting improved patient outcomes and enhanced clinical assessment within the service.Due to the IOPI Pro 3.1 being regarded as clinical standard the Health Board the decision has been made to publish a Transparency Notice in order to direct award the contract to Severn Healthcare Technologies Limited. Severn Healthcare Technologies Limited are the only UK distributer and training provider of the IOPI Pro.

Purchase of Cascination IR

Cardiff and Vale University Health Board, intends to award a contract to Medivate for the one off purchase of Geister Peripheral and Major Vascular Access Instruments. The University Hospital of Wales (UHW) operates as a Major Trauma Centre and provides regional vascular and trauma services, receiving referrals from across South and West Wales. Theatre capacity is being expanded, including the development of additional major trauma and hybrid theatres to support high‑complexity trauma and vascular surgery.Peripheral and major vascular instrument sets are required for use across multiple theatre settings, including elective vascular theatres, CEPOD emergency theatres, Major Trauma Centre theatres, and hybrid/endovascular suites. These instrument sets support the delivery of abdominal aortic repairs, carotid endarterectomies, lower limb revascularisation procedures, trauma‑related vascular repairs, and conversions from endovascular to open surgery.The existing instrument inventory currently comprises three major vascular sets and four peripheral sets, which are fully utilised for elective, endovascular, and reserved damage‑control activity. This utilisation limits availability for urgent and out‑of‑hours procedures. The procurement of additional instrument trays is required to maintain operational capacity, ensure cover for emergency, weekend, and trauma activity, and support continuity of elective services across planned and unplanned care pathways.

National framework for the provision of Insulin Pumps, CGM, associated diabetes consumables and technology.

Hywel Dda University Health Board (HDUHB) has identified a requirement to purchase an Oral Performance Instrument for use within the Speech and Language Therapy Department. The Iowa Oral Performance Instrument is a clinical tool used to measure and improve the strength of the tongue and lips. Procurement of this device will support the assessment and treatment of patients with Dysphagia (swallowing disorders), assist with speech therapy interventions, and aid rehabilitation following illness or injury. The device will enable clinicians to objectively measure oral muscle strength and deliver targeted therapy programmes, supporting improved patient outcomes and enhanced clinical assessment within the service.Due to the IOPI Pro 3.1 being regarded as clinical standard the Health Board the decision has been made to publish a Transparency Notice in order to direct award the contract to Severn Healthcare Technologies Limited. Severn Healthcare Technologies Limited are the only UK distributer and training provider of the IOPI Pro.

Provision of Fungitell Kinetic Assay for Public Health Wales for the detection of (1-3)-Beta-D-glucan (BDG) in body fluids, particularly blood, for the diagnostic indication of fungal infection in line with the NICE sepsis pathway testing regime. Fungitell is the only kit system specified within the NICE guidelines as part of the sepsis pathway that is clinically validated.